X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs SUN PHARMA - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB SUN PHARMA DR. REDDYS LAB/
SUN PHARMA
 
P/E (TTM) x 30.5 25.9 118.0% View Chart
P/BV x 3.0 3.8 79.1% View Chart
Dividend Yield % 0.9 0.6 148.5%  

Financials

 DR. REDDYS LAB   SUN PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-17
SUN PHARMA
Mar-17
DR. REDDYS LAB/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs3,397842 403.4%   
Low Rs2,560572 447.2%   
Sales per share (Unadj.) Rs856.5131.6 650.8%  
Earnings per share (Unadj.) Rs78.032.7 238.4%  
Cash flow per share (Unadj.) Rs139.938.0 368.4%  
Dividends per share (Unadj.) Rs20.003.50 571.4%  
Dividend yield (eoy) %0.70.5 135.7%  
Book value per share (Unadj.) Rs739.8152.7 484.5%  
Shares outstanding (eoy) m165.742,399.26 6.9%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x3.55.4 64.7%   
Avg P/E ratio x38.221.6 176.7%  
P/CF ratio (eoy) x21.318.6 114.3%  
Price / Book Value ratio x4.04.6 86.9%  
Dividend payout %25.710.7 239.7%   
Avg Mkt Cap Rs m493,6321,696,877 29.1%   
No. of employees `00022.717.5 129.5%   
Total wages/salary Rs m31,06849,023 63.4%   
Avg. sales/employee Rs Th6,259.018,028.3 34.7%   
Avg. wages/employee Rs Th1,369.82,798.8 48.9%   
Avg. net profit/employee Rs Th569.74,479.5 12.7%   
INCOME DATA
Net Sales Rs m141,961315,784 45.0%  
Other income Rs m1,7156,232 27.5%   
Total revenues Rs m143,676322,016 44.6%   
Gross profit Rs m24,722100,893 24.5%  
Depreciation Rs m10,26612,648 81.2%   
Interest Rs m6343,998 15.9%   
Profit before tax Rs m15,53790,479 17.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m34999 351.5%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,96512,116 24.5%   
Profit after tax Rs m12,92178,462 16.5%  
Gross profit margin %17.431.9 54.5%  
Effective tax rate %19.113.4 142.5%   
Net profit margin %9.124.8 36.6%  
BALANCE SHEET DATA
Current assets Rs m96,837329,537 29.4%   
Current liabilities Rs m84,199178,870 47.1%   
Net working cap to sales %8.947.7 18.7%  
Current ratio x1.21.8 62.4%  
Inventory Days Days7379 92.9%  
Debtors Days Days9883 117.3%  
Net fixed assets Rs m102,552204,766 50.1%   
Share capital Rs m8292,399 34.6%   
"Free" reserves Rs m121,792363,997 33.5%   
Net worth Rs m122,621366,397 33.5%   
Long term debt Rs m5,44914,361 37.9%   
Total assets Rs m218,165614,102 35.5%  
Interest coverage x25.523.6 107.9%   
Debt to equity ratio x00 113.4%  
Sales to assets ratio x0.70.5 126.5%   
Return on assets %6.213.4 46.3%  
Return on equity %10.521.4 49.2%  
Return on capital %12.924.8 51.9%  
Exports to sales %54.60-   
Imports to sales %9.40-   
Exports (fob) Rs m77,520NA-   
Imports (cif) Rs m13,274NA-   
Fx inflow Rs m81,67044,118 185.1%   
Fx outflow Rs m26,35524,484 107.6%   
Net fx Rs m55,31519,634 281.7%   
CASH FLOW
From Operations Rs m21,44470,822 30.3%  
From Investments Rs m-18,404-42,216 43.6%  
From Financial Activity Rs m-3,692-22,854 16.2%  
Net Cashflow Rs m-1,1446,107 -18.7%  

Share Holding

Indian Promoters % 25.5 63.7 40.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 5.1 105.3%  
FIIs % 35.3 23.0 153.5%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 8.3 184.3%  
Shareholders   75,885 133,026 57.0%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   DISHMAN PHARMA  ELDER PHARMA  SUVEN LIFE  PANACEA BIOTECH  WOCKHARDT LTD.  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Feb 16, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS